Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
J Surg Oncol. 2012 Aug 1;106(2):144-8. doi: 10.1002/jso.23055. Epub 2012 Jan 27.
Colorectal cancer (CRC) rarely metastasizes to the brain, and the incidence rate has been reported to be 1-2%. Unfortunately, the median survival for patients with brain metastasis (BM) from CRC is short. In this study, we retrospectively investigated the BM from CRC and examined the prognostic factors.
We retrospectively analyzed 29 CRC patients who developed BM; the lesions were diagnosed synchronously in 1 patient and metachronously in 28 patients.
After BM, the median survival time was 7.4 months. In the groups of patients who underwent surgical resection and radiation therapy, the median survival times were 8.3 and 7.4 months, respectively. The difference between the two groups was not statistically significant. The curability of the therapy for BM, number of BM, number of metastatic organs including the brain, and the CEA level at the time of treatment of the BM were significantly associated with the cancer-specific survival (P = 0.0044, 0.0229, 0.0019, and 0.0205, respectively).
The prognosis of patients with BM from CRC was associated with the curability of the therapy for BM, number of metastatic organs, and the serum CEA level. The modality of treatment had no significant impact on the outcome.
结直肠癌（CRC）很少转移到脑部，其发病率据报道为 1-2%。不幸的是，CRC 脑转移（BM）患者的中位生存期较短。在本研究中，我们回顾性调查了 CRC 的 BM，并检查了预后因素。
我们回顾性分析了 29 例发生 BM 的 CRC 患者；1 例为同步诊断，28 例为异时诊断。
发生 BM 后，中位生存时间为 7.4 个月。在接受手术切除和放射治疗的患者组中，中位生存时间分别为 8.3 个月和 7.4 个月，两组间差异无统计学意义。BM 的治疗可治愈性、BM 的数量、包括脑在内的转移性器官的数量以及治疗 BM 时的 CEA 水平与癌症特异性生存显著相关（P=0.0044、0.0229、0.0019 和 0.0205）。
CRC 患者 BM 的预后与 BM 的治疗可治愈性、转移性器官的数量和血清 CEA 水平有关。治疗方式对预后没有显著影响。
